AWWA JAW49825 PDF

AWWA JAW49825 PDF

Name:
AWWA JAW49825 PDF

Published Date:
04/01/1999

Status:
Active

Description:

Journal AWWA - Benefits and Costs of the IESWTR

Publisher:
American Water Works Association

Document status:
Active

Format:
Electronic (PDF)

Delivery time:
10 minutes

Delivery time (for Russian version):
200 business days

SKU:

Choose Document Language:
$9
Need Help?
Like the Stage 1 Disinfectants/Disinfection Byproducts Rule, the Interim Enhanced Surface Water Treatment Rule (IESWTR) grew out of the negotiated rulemaking the US Environmental Protection Agency convened in 1992-93 under the Federal Advisory Committee Act (FACA). The rulemaking sought to develop a consensus approach to simultaneously addressing potential health risks posed by disinfection by-products (DBPs) and waterborne pathogens. Even though the process was complicated by the possibility of making inadvertent risk-risk tradeoffs between protection from DBPs and protection from pathogens and uncertainties affecting the assessment of both risks, the regulatory-negotiations committee was able to devise a well-balanced, staged approach to regulation. A second FACA committee finalized the approach in 1996-97. This article summarizes the microbial side of the benefit-cost analysis and the explicit uncertainty analysis that was used to inform the stakeholders and the negotiators. Includes 21 references, tables, figures.
Edition : Vol. 91 - No. 4
File Size : 1 file , 730 KB
Note : This product is unavailable in Ukraine, Russia, Belarus
Number of Pages : 11
Published : 04/01/1999

History


Related products

AWWA ACE91144
Published Date: 01/01/1991
Penetration: Math or Reality Local Agency Perspective
$7.2
AWWA JAW49827
Published Date: 04/01/1999
Journal AWWA - Isotopic Uranium Activity Ratios in California Groundwater
$9
AWWA JAW49826
Published Date: 04/01/1999
Journal AWWA - Predicting Full-Scale TOC Removal
$9
AWWA JAW49824
Published Date: 04/01/1999
Journal AWWA - Benefit-Cost Analysis of the Stage 1 D/DBP Rule
$9

Best-Selling Products

Alzheimer's Disease Report
Published Date: 12/01/2018
$2398.5
Cystic Fibrosis Disease Report
Published Date: 04/01/2019
$2398.5
Multiple Sclerosis Disease Report
Published Date: 12/01/2018
$2398.5
Non-Alcoholic Steatohepatitis Disease Report
Published Date: 12/01/2018
$2398.5
Non-Hodgkin's Lymphoma Disease Report
Published Date: 12/01/2018
$2398.5